



## 2024 Recommended Pediatric and Adolescent Immunization Schedule (Maintains CPP Eligibility)

Manufacturer	Brand Name	Vaccine	Birth	1 mo	2 mos	4 mos	6 mos	9 mos	12 mos	15 mos	18 mos	19-23 mos	2-3 yrs	4-6 yrs	7-10 yrs	11-12 yrs	13-15 yrs	16-18 yrs			
Sanofi	Beyfortus™	RSV-mAb	1st Dose depending on maternal RSV vaccination					1 dose thru 19 months													
Merck MSP	Recombivax HB® Vaxelis®	Hepatitis B	1st	2nd				3rd													
Merck	RotaTec®	Rotavirus (oral)		1st	2nd	3rd															
Sanofi Sanofi MSP Sanofi	Daptacel® Pentacel® Vaxelis® Quadracel®	Diphtheria, Tetanus, Acellular Pertussis (DTaP)		1st	2nd	3rd			4th					5th							
Sanofi Merck Sanofi MSP	ActHIB® PedVaxHIB® Pentacel® Vaxelis®	Haemophilus Influenzae Type B		1st	2nd	3rd		4th													
Pfizer Merck	Prenvar 20® Vaxneuvance™	Pneumococcal Conjugate		1st	2nd	3rd		4th													
Sanofi Sanofi MSP Sanofi	IPOl® Pentacel® Vaxelis® Quadracel®	Inactivated Polio		1st	2nd			3rd						4th							
Various	Various	COVID-19	1 or more doses of updated vaccine																		
Sanofi	Fluzone®	Influenza (IIV)	Annual Vaccination 1 or 2 doses											Annual Vaccination 1 dose only							
<b>OR</b>			<b>OR</b>																		
AstraZeneca	FluMist®	Influenza (LAIV4)	Annual Vaccination 1 or 2 doses											Annual Vaccination 1 dose only							
Merck	MMRII® ProQuad®	Measles, Mumps, Rubella							1st					2nd							
Merck	Varivax® ProQuad®	Varicella							1st					2nd							
Merck	Vaqa®	Hepatitis A							2 dose series												
Sanofi	Adacel®	Tetanus, Diphtheria, Acellular Pertussis (Tdap)																	Tdap		
Merck	Gardasil 9®	Human Papillomavirus																	2 dose series		
Sanofi Pfizer	MenQuadfi® Penbraya™	MenACWY MenABCWY		1st																2nd	
Pfizer	Trumenba® Penbraya™	MenB MenABCWY																			
Pfizer	Abrysvo™	RSV maternal																			Seasonal administration during pregnancy
Sanofi	Dengvaxia®	Dengue																			seropositive in endemic dengue areas
	JYNNEOS vaccine	Monkeypox																			

Range of recommended ages
  Catch-up vaccination
  High risk population
  Non-high-risk groups may receive vaccine, subject to shared clinical decision making

The information in this document is proprietary and confidential and may not be disclosed without the written consent of Children's Practicing Pediatricians. This information may be used solely by medical practices and practitioners for the purpose of evaluating the CPP Vaccine Buying Group. The information can become outdated quickly and should be used only as an illustration of some of the benefits of the CPP Program. No clinical, medical or professional advice is being rendered and readers should discuss specific situations within each practice and/or with their professional advisors. Copyright 2024 by Children's Practicing Pediatricians. All rights reserved.